Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.50 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888816 | 1.00 | MEN1 (0.51) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| Potassium SCHEMBL10738982 | 0.99 | MEN1 (0.50) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL10738974 | 0.99 | MEN1 (0.50) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL11111293 | 0.94 | HSD17B10 (0.56) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL10627592 | 0.93 | MEN1 (0.47) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL11264415 | 0.92 | MEN1 (0.50) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL11109377 | 0.92 | MEN1 (0.50) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL7983269 | 0.91 | ESR2 (0.49) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL7789773 | 0.91 | HSD17B10 (0.47) | MEN1KMT2AHSD17B10CYP2C9LMNA | |
| SCHEMBL10656876 | 0.91 | HSD17B10 (0.47) | MEN1KMT2AHSD17B10CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-07-25 | — | — | US | claimed |
| US-4316043-A | ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1982-02-16 | — | — | US | claimed |
| US-11000492-B2 | Fluorenone compound for the treatment of gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-11 | — | — | US | disclosed |
| US-11000492-B2 | Fluorenone compound for the treatment of gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200246289-A1 | FLUORENONE COMPOUND FOR THE TREATMENT OF GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200246289-A1 | FLUORENONE COMPOUND FOR THE TREATMENT OF GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-08-06 | — | — | US | disclosed |
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-07-25 | — | — | US | disclosed |
| EP-1409681-A2 | PROTEINS AND NUCLEIC ACIDS ENCODING SAME | Curagen Corporation (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002068649-A2 | PROTEINS AND NUCLEIC ACIDS ENCODING SAME | CURAGEN CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| US-4797391-A | TREATMENT OF TRAUMA TO THE BRAIN | MERCK & CO., INC. (US) | 1989-01-10 | — | — | US | disclosed |
| US-4782073-A | BRAIN EDEMA | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0027948-B1 | TETRAHYDRO-FLUORENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | disclosed |
| US-4356314-A | [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4356313-A | [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts | MERCK & CO., INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4337354-A | BRAIN AND SPINAL CHORD DAMAGE | MERCK & CO., INC. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4317922-A | [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives | MERCK & CO., INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4316043-A | ANTIEDEMIC AGENTS | MERCK & CO., INC. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0027948-A1 | Tetrahydro-fluorene compounds, processes for their preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1981-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000492-B2 | Fluorenone compound for the treatment of gout | SLC10A1, PCSK9, PCSK7 | MEN1 2313/4885KMT2A 3230/4885HSD17B10 94/4885 |
| US-20200246289-A1 | FLUORENONE COMPOUND FOR THE TREATMENT OF GOUT | SLC10A1, PCSK9, PCSK7 | MEN1 2313/4885KMT2A 3230/4885HSD17B10 94/4885 |
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | ALDH1A2, GLI2, MMP1 | MEN1 3900/4885KMT2A 4687/4885HSD17B10 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.